You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFlunisolide
Accession NumberDB00180  (APRD00976)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionFlunisolide (marketed as AeroBid, Nasalide, Nasarel) is a corticosteroid often prescribed as treatment for allergic rhinitis. The principle mechanism of action of flunisolide is to activate glucocorticoid receptors. It also has anti-inflammatory action.
Structure
Thumb
Synonyms
Flunisolida
Flunisolide
Flunisolide anhydrous
Flunisolidum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AerospanAerosol, metered80 ug/1Respiratory (inhalation)MEDA Pharmaceuticals2012-03-01Not applicableUs
AerospanAerosol, metered80 ug/1Respiratory (inhalation)Acton Pharmaceuticals, Inc.2012-03-01Not applicableUs
Bronalide Inhal 250mcg/aemAerosol, metered250 mcgRespiratory (inhalation)Boehringer Ingelheim (Canada) Ltd Ltee1988-12-311999-02-15Canada
Novo-flunisolideSpray25 mcgNasalNovopharm Limited1998-06-302005-08-10Canada
PMS-flunisolideSpray0.025 %NasalPharmascience Inc1994-12-312009-08-27Canada
Ratio-flunisolideSpray25 mcgNasalRatiopharm Inc Division Of Teva Canada Limited1993-12-312010-08-02Canada
RhinalarSpray.025 %NasalSyntex Inc.1978-12-311996-09-30Canada
Rhinalar Nasal MistSolution; Spray25 mcgNasalIvax Laboratories Incorporated1996-12-312015-10-26Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-flunisolide Nasal SpraySpray, metered0.25 mgNasalApotex Inc2000-03-10Not applicableCanada
FlunisolideSolution.25 mg/mLNasalPhysicians Total Care, Inc.2003-05-23Not applicableUs
FlunisolideSolution.25 mg/mLNasalBausch & Lomb Incorporated2002-02-20Not applicableUs
FlunisolideSpray, metered.25 mg/mLNasalRising Pharmaceuticals, Inc2006-08-03Not applicableUs
FlunisolideSolution.25 mg/mLNasalREMEDYREPACK INC.2016-02-17Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AeroBidRoche
BronalideKrewel
NasalideTeva Santé
NasarelNot Available
SyntarisTeva
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Flunisolide acetate
4533-89-5
Thumb
  • InChI Key: WEGNFRKBIKYVLC-XTLNBZDDSA-N
  • Monoisotopic Mass: 476.221031566
  • Average Mass: 476.541
DBSALT001846
Flunisolide hemihydrate
77326-96-6
Thumb
  • InChI Key: MIXMJCQRHVAJIO-TZHJZOAOSA-N
  • Monoisotopic Mass: 886.431498447
  • Average Mass: 887.024
DBSALT001845
Categories
UNII78M02AA8KF
CAS number3385-03-3
WeightAverage: 434.4977
Monoisotopic: 434.210466929
Chemical FormulaC24H31FO6
InChI KeyXSFJVAJPIHIPKU-XWCQMRHXSA-N
InChI
InChI=1S/C24H31FO6/c1-21(2)30-19-9-14-13-8-16(25)15-7-12(27)5-6-22(15,3)20(13)17(28)10-23(14,4)24(19,31-21)18(29)11-26/h5-7,13-14,16-17,19-20,26,28H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,20+,22-,23-,24+/m0/s1
IUPAC Name
(1S,2S,4R,8S,9S,11S,12S,13R,19S)-19-fluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosa-14,17-dien-16-one
SMILES
[H][C@@]12C[C@@]3([H])[C@]4([H])C[[email protected]](F)C5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO
Pharmacology
IndicationFor the maintenance treatment of asthma as a prophylactic therapy.
Structured Indications
PharmacodynamicsFlunisolide is a synthetic corticosteroid. It is administered either as an oral metered-dose inhaler for the treatment of asthma or as a nasal spray for treating allergic rhinitis. Corticosteroids are naturally occurring hormones that prevent or suppress inflammation and immune responses. When given as an intranasal spray, flunisolide reduces watery nasal discharge (rhinorrhea), nasal congestion, postnasal drip, sneezing, and itching oat the back of the throat that are common allergic symptoms.
Mechanism of actionFlunisolide is a glucocorticoid receptor agonist. The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Flunisolide binds to plasma transcortin, and it becomes active when it is not bound to transcortin.
TargetKindPharmacological actionActionsOrganismUniProt ID
Glucocorticoid receptorProteinyes
agonist
HumanP04150 details
Related Articles
AbsorptionAbsorbed rapidly
Volume of distributionNot Available
Protein bindingApproximately 40% after oral inhalation
Metabolism

Primarily hepatic, converted to the S beta-OH metabolite.

Route of eliminationNot Available
Half life1.8 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Flunisolide is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Flunisolide.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Acetovanillone is combined with Flunisolide.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Flunisolide.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Flunisolide.Approved
AldesleukinFlunisolide may decrease the antineoplastic activities of Aldesleukin.Approved
ALT-110The risk or severity of adverse effects can be increased when Flunisolide is combined with ALT-110.Investigational
Aluminum hydroxideThe bioavailability of Flunisolide can be decreased when combined with Aluminum hydroxide.Approved
Aluminum phosphateThe bioavailability of Flunisolide can be decreased when combined with Aluminum phosphate.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Flunisolide is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Flunisolide.Approved
AmiodaroneThe metabolism of Flunisolide can be decreased when combined with Amiodarone.Approved, Investigational
Amphotericin BFlunisolide may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Flunisolide.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Flunisolide.Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Flunisolide.Approved, Investigational
AprepitantThe serum concentration of Flunisolide can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe metabolism of Flunisolide can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Flunisolide can be decreased when combined with Atomoxetine.Approved
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Flunisolide.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Flunisolide.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Flunisolide.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Flunisolide.Approved, Investigational
BazedoxifeneThe serum concentration of Flunisolide can be increased when it is combined with Bazedoxifene.Approved, Investigational
BendroflumethiazideFlunisolide may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Flunisolide.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Flunisolide.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Flunisolide.Investigational
BexaroteneThe serum concentration of Flunisolide can be decreased when it is combined with Bexarotene.Approved, Investigational
Bismuth SubcitrateThe bioavailability of Flunisolide can be decreased when combined with Bismuth Subcitrate.Approved
BoceprevirThe metabolism of Flunisolide can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Flunisolide can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Flunisolide can be decreased when it is combined with Bosentan.Approved, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Flunisolide.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Flunisolide.Investigational
BumetanideFlunisolide may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Flunisolide.Approved, Nutraceutical
Calcium carbonateThe bioavailability of Flunisolide can be decreased when combined with Calcium carbonate.Approved
CarbamazepineThe metabolism of Flunisolide can be increased when combined with Carbamazepine.Approved, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Flunisolide.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Flunisolide.Experimental
CDX-110The risk or severity of adverse effects can be increased when Flunisolide is combined with CDX-110.Investigational
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Flunisolide.Approved, Investigational
CeritinibThe serum concentration of Flunisolide can be increased when it is combined with Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Flunisolide.Approved, Vet Approved
ChlorothiazideFlunisolide may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Flunisolide can be increased when it is combined with Chlorotrianisene.Withdrawn
ChlorthalidoneFlunisolide may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Flunisolide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Flunisolide is combined with Cinoxacin.Approved, Withdrawn
CiprofloxacinThe risk or severity of adverse effects can be increased when Flunisolide is combined with Ciprofloxacin.Approved, Investigational
ClarithromycinThe metabolism of Flunisolide can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Flunisolide can be decreased when combined with Clemastine.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Flunisolide.Approved
ClotrimazoleThe metabolism of Flunisolide can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Flunisolide can be decreased when combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Flunisolide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Flunisolide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Flunisolide can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Flunisolide can be increased when it is combined with Conjugated Equine Estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Flunisolide.Approved
CoumaphosThe risk or severity of adverse effects can be increased when Flunisolide is combined with Coumaphos.Vet Approved
CrizotinibThe metabolism of Flunisolide can be decreased when combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Flunisolide.Investigational
CyclosporineThe metabolism of Flunisolide can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Flunisolide.Investigational
DabrafenibThe serum concentration of Flunisolide can be decreased when it is combined with Dabrafenib.Approved
DarunavirThe metabolism of Flunisolide can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Flunisolide can be increased when it is combined with Dasatinib.Approved, Investigational
DecamethoniumThe risk or severity of adverse effects can be increased when Flunisolide is combined with Decamethonium.Approved
DeferasiroxThe serum concentration of Flunisolide can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Flunisolide can be decreased when combined with Delavirdine.Approved
DemecariumThe risk or severity of adverse effects can be increased when Flunisolide is combined with Demecarium.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Flunisolide.Investigational
DexamethasoneThe serum concentration of Flunisolide can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DichlorvosThe risk or severity of adverse effects can be increased when Flunisolide is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Flunisolide.Approved, Vet Approved
DienestrolThe serum concentration of Flunisolide can be increased when it is combined with Dienestrol.Approved
DiethylstilbestrolThe serum concentration of Flunisolide can be increased when it is combined with Diethylstilbestrol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Flunisolide.Approved
DihydroergotamineThe metabolism of Flunisolide can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneFlunisolide may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DiltiazemThe metabolism of Flunisolide can be decreased when combined with Diltiazem.Approved
DonepezilThe risk or severity of adverse effects can be increased when Flunisolide is combined with Donepezil.Approved
DoxycyclineThe metabolism of Flunisolide can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Flunisolide can be decreased when combined with Dronedarone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Flunisolide.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Flunisolide.Investigational
E6201The risk or severity of adverse effects can be increased when E6201 is combined with Flunisolide.Investigational
EbselenThe risk or severity of adverse effects can be increased when Ebselen is combined with Flunisolide.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Flunisolide is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Flunisolide is combined with Edrophonium.Approved
EfavirenzThe serum concentration of Flunisolide can be decreased when it is combined with Efavirenz.Approved, Investigational
EnoxacinThe risk or severity of adverse effects can be increased when Flunisolide is combined with Enoxacin.Approved
EnzalutamideThe serum concentration of Flunisolide can be decreased when it is combined with Enzalutamide.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Flunisolide.Approved
ErythromycinThe metabolism of Flunisolide can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Flunisolide can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstradiolThe serum concentration of Flunisolide can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Flunisolide can be increased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Flunisolide can be increased when it is combined with Estrone.Approved
Etacrynic acidFlunisolide may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Flunisolide.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Flunisolide can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Flunisolide.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Flunisolide.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Flunisolide.Approved, Investigational
EtravirineThe serum concentration of Flunisolide can be decreased when it is combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Flunisolide.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Flunisolide.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Flunisolide.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Flunisolide.Approved
FenthionThe risk or severity of adverse effects can be increased when Flunisolide is combined with Fenthion.Vet Approved
FleroxacinThe risk or severity of adverse effects can be increased when Flunisolide is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Flunisolide.Approved, Withdrawn
FluconazoleThe metabolism of Flunisolide can be decreased when combined with Fluconazole.Approved
FlumequineThe risk or severity of adverse effects can be increased when Flunisolide is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Flunisolide.Vet Approved
FluoxymesteroneFlunisolide may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Flunisolide.Approved, Investigational
FluvoxamineThe metabolism of Flunisolide can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Flunisolide can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Flunisolide can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Flunisolide can be increased when combined with Fosphenytoin.Approved
FurosemideFlunisolide may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Flunisolide can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Flunisolide is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Flunisolide is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Flunisolide is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Flunisolide is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Flunisolide is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Flunisolide can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Flunisolide is combined with GI-5005.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Flunisolide is combined with Ginkgo biloba.Approved, Nutraceutical
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Flunisolide.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Flunisolide is combined with Grepafloxacin.Withdrawn
HexestrolThe serum concentration of Flunisolide can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Flunisolide.Investigational
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Flunisolide.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Flunisolide is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Flunisolide.Approved, Investigational
HydrochlorothiazideFlunisolide may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideFlunisolide may increase the hypokalemic activities of Hydroflumethiazide.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Flunisolide.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Flunisolide.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Flunisolide.Approved
IdelalisibThe serum concentration of Flunisolide can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Flunisolide can be decreased when combined with Imatinib.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Flunisolide.Approved
IndapamideFlunisolide may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe metabolism of Flunisolide can be decreased when combined with Indinavir.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Flunisolide.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Flunisolide.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Flunisolide is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Flunisolide is combined with INGN 225.Investigational
IsavuconazoniumThe metabolism of Flunisolide can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Flunisolide is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Flunisolide.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Flunisolide.Withdrawn
IsradipineThe metabolism of Flunisolide can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Flunisolide can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Flunisolide can be increased when it is combined with Ivacaftor.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Flunisolide.Experimental
KetoconazoleThe metabolism of Flunisolide can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Flunisolide.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Flunisolide.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Flunisolide.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Flunisolide is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Flunisolide.Investigational
LomefloxacinThe risk or severity of adverse effects can be increased when Flunisolide is combined with Lomefloxacin.Approved
LopinavirThe metabolism of Flunisolide can be decreased when combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Flunisolide.Approved
LovastatinThe metabolism of Flunisolide can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Flunisolide is combined with Loxapine.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Flunisolide.Approved
LuliconazoleThe serum concentration of Flunisolide can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Flunisolide can be increased when combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Flunisolide.Approved, Investigational
MagaldrateThe bioavailability of Flunisolide can be decreased when combined with Magaldrate.Withdrawn
Magnesium carbonateThe bioavailability of Flunisolide can be decreased when combined with Magnesium carbonate.Approved
Magnesium hydroxideThe bioavailability of Flunisolide can be decreased when combined with Magnesium hydroxide.Approved
Magnesium oxideThe bioavailability of Flunisolide can be decreased when combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Flunisolide.Approved
Magnesium TrisilicateThe bioavailability of Flunisolide can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Flunisolide is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Flunisolide.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Flunisolide.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Flunisolide.Approved
MefloquineThe risk or severity of adverse effects can be increased when Flunisolide is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Flunisolide.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Flunisolide is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Flunisolide.Approved
MestranolThe serum concentration of Flunisolide can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Flunisolide.Withdrawn
MethallenestrilThe serum concentration of Flunisolide can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideFlunisolide may increase the hypokalemic activities of Methyclothiazide.Approved
MethyltestosteroneFlunisolide may increase the fluid retaining activities of Methyltestosterone.Approved
MetolazoneFlunisolide may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of Flunisolide can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Flunisolide is combined with Minaprine.Approved
MitotaneThe serum concentration of Flunisolide can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Flunisolide.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Flunisolide.Investigational
ModafinilThe serum concentration of Flunisolide can be decreased when it is combined with Modafinil.Approved, Investigational
MoxifloxacinThe risk or severity of adverse effects can be increased when Flunisolide is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Flunisolide.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Flunisolide.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Flunisolide.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Flunisolide.Investigational
NafcillinThe serum concentration of Flunisolide can be decreased when it is combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Flunisolide.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Flunisolide is combined with Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Flunisolide.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Flunisolide.Investigational
NefazodoneThe metabolism of Flunisolide can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Flunisolide can be decreased when combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Flunisolide is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Flunisolide is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Flunisolide.Approved
NetupitantThe serum concentration of Flunisolide can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Flunisolide can be increased when combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Flunisolide is combined with Nicorandil.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Flunisolide.Approved
NilotinibThe metabolism of Flunisolide can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Flunisolide.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Flunisolide.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Flunisolide is combined with Norfloxacin.Approved
OfloxacinThe risk or severity of adverse effects can be increased when Flunisolide is combined with Ofloxacin.Approved
OlaparibThe metabolism of Flunisolide can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Flunisolide.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Flunisolide.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Flunisolide.Vet Approved
OsimertinibThe serum concentration of Flunisolide can be increased when it is combined with Osimertinib.Approved
OxandroloneFlunisolide may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Flunisolide.Approved
OxymetholoneFlunisolide may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Flunisolide.Withdrawn
PalbociclibThe serum concentration of Flunisolide can be increased when it is combined with Palbociclib.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Flunisolide.Approved
PazufloxacinThe risk or severity of adverse effects can be increased when Flunisolide is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Flunisolide is combined with Pefloxacin.Approved
PentobarbitalThe metabolism of Flunisolide can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe metabolism of Flunisolide can be increased when combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Flunisolide.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Flunisolide.Approved, Vet Approved
PhenytoinThe metabolism of Flunisolide can be increased when combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Flunisolide is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Flunisolide.Approved, Investigational
PiretanideFlunisolide may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Flunisolide.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Flunisolide.Approved, Investigational
Polyestradiol phosphateThe serum concentration of Flunisolide can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideFlunisolide may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe metabolism of Flunisolide can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PrimidoneThe metabolism of Flunisolide can be increased when combined with Primidone.Approved, Vet Approved
PromestrieneThe serum concentration of Flunisolide can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Flunisolide.Approved
PrulifloxacinThe risk or severity of adverse effects can be increased when Flunisolide is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Flunisolide.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Flunisolide is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Flunisolide can be increased when it is combined with Quinestrol.Approved
QuinethazoneFlunisolide may increase the hypokalemic activities of Quinethazone.Approved
Rabies vaccineThe risk or severity of adverse effects can be increased when Flunisolide is combined with Rabies vaccine.Approved
RanolazineThe metabolism of Flunisolide can be decreased when combined with Ranolazine.Approved, Investigational
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Flunisolide.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Flunisolide.Experimental, Investigational
RifabutinThe metabolism of Flunisolide can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Flunisolide can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Flunisolide can be increased when combined with Rifapentine.Approved
RitonavirThe metabolism of Flunisolide can be decreased when combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Flunisolide is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Flunisolide.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when Flunisolide is combined with Rosoxacin.Approved
S EquolThe serum concentration of Flunisolide can be increased when it is combined with S Equol.Investigational
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Flunisolide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Flunisolide.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Flunisolide.Approved
SaquinavirThe metabolism of Flunisolide can be decreased when combined with Saquinavir.Approved, Investigational
SecoisolariciresinolThe serum concentration of Flunisolide can be increased when it is combined with Secoisolariciresinol.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Flunisolide.Approved, Investigational
SildenafilThe metabolism of Flunisolide can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Flunisolide can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Flunisolide can be increased when it is combined with Simeprevir.Approved
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Flunisolide.Approved
SparfloxacinThe risk or severity of adverse effects can be increased when Flunisolide is combined with Sparfloxacin.Approved
SRP 299The risk or severity of adverse effects can be increased when Flunisolide is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Flunisolide.Investigational
St. John's WortThe serum concentration of Flunisolide can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololFlunisolide may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Flunisolide can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Flunisolide.Approved
SulfisoxazoleThe metabolism of Flunisolide can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Flunisolide.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Flunisolide.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Flunisolide can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Flunisolide can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Flunisolide is combined with Tacrine.Withdrawn
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Flunisolide.Approved
TelithromycinThe metabolism of Flunisolide can be decreased when combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Flunisolide is combined with Temafloxacin.Withdrawn
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Flunisolide.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Flunisolide.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Flunisolide.Approved
TestosteroneFlunisolide may increase the fluid retaining activities of Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Flunisolide is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Flunisolide.Approved
TiboloneThe serum concentration of Flunisolide can be increased when it is combined with Tibolone.Approved
TiclopidineThe metabolism of Flunisolide can be decreased when combined with Ticlopidine.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Flunisolide.Investigational
TocilizumabThe serum concentration of Flunisolide can be decreased when it is combined with Tocilizumab.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Flunisolide.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Flunisolide.Approved
TorasemideFlunisolide may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Flunisolide.Approved, Investigational
TrichlorfonThe risk or severity of adverse effects can be increased when Flunisolide is combined with Trichlorfon.Vet Approved
TrichlormethiazideFlunisolide may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Flunisolide.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Flunisolide is combined with Trovafloxacin.Approved, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Flunisolide is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Flunisolide.Investigational, Withdrawn
VenlafaxineThe metabolism of Flunisolide can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Flunisolide can be decreased when combined with Verapamil.Approved
VoriconazoleThe metabolism of Flunisolide can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinFlunisolide may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Flunisolide.Approved
ZeranolThe serum concentration of Flunisolide can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Flunisolide.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Flunisolide can be decreased when combined with Ziprasidone.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Flunisolide.Withdrawn
Food InteractionsNot Available
References
Synthesis Reference

Richard E. Jones, Jacquelyn A. Smithers, “Process for preparing flunisolide.” U.S. Patent US4273710, issued July, 1965.

US4273710
General ReferencesNot Available
External Links
ATC CodesR01AD04R03BA03
AHFS Codes
  • 52:08.08
PDB EntriesNot Available
FDA labelDownload (4.31 MB)
MSDSDownload (74.3 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9865
Blood Brain Barrier+0.9683
Caco-2 permeable+0.5
P-glycoprotein substrateSubstrate0.7912
P-glycoprotein inhibitor INon-inhibitor0.5674
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.8304
CYP450 2C9 substrateNon-substrate0.8679
CYP450 2D6 substrateNon-substrate0.8856
CYP450 3A4 substrateSubstrate0.6964
CYP450 1A2 substrateNon-inhibitor0.9327
CYP450 2C9 inhibitorNon-inhibitor0.9394
CYP450 2D6 inhibitorNon-inhibitor0.9559
CYP450 2C19 inhibitorNon-inhibitor0.9311
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8806
Ames testNon AMES toxic0.7682
CarcinogenicityNon-carcinogens0.9174
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.7033 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9838
hERG inhibition (predictor II)Non-inhibitor0.671
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Roche palo alto llc
  • Acton pharmaceuticals inc
  • Apotex inc richmond hill
  • Bausch and lomb pharmaceuticals inc
  • Qpharma llc
  • Ivax research inc
  • Teva branded pharmaceutical products r and d inc
Packagers
Dosage forms
FormRouteStrength
Aerosol, meteredRespiratory (inhalation)80 ug/1
Spray, meteredNasal0.25 mg
Aerosol, meteredRespiratory (inhalation)250 mcg
SolutionNasal.25 mg/mL
Spray, meteredNasal.25 mg/mL
SprayNasal0.025 %
SprayNasal25 mcg
SprayNasal.025 %
Solution; sprayNasal25 mcg
Prices
Unit descriptionCostUnit
Aerobid 250 mcg/act Aerosol 7 gm Inhaler101.95USD inhaler
Aerobid-M 250 mcg/act Aerosol 7 gm Inhaler101.95USD inhaler
Flunisolide 29 mcg/act Solution 25ml Bottle57.16USD bottle
Flunisolide 0.025% Solution 25ml Bottle48.35USD bottle
Aerobid aerosol with adapter14.0USD g
Aerobid-m aerosol with adapter14.0USD g
Flunisolide 29 mcg-0.025% spray2.2USD ml
Nasarel 29 mcg-0.025% spray1.98USD ml
Apo-Flunisolide 0.025 % Spray0.62USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5776433 No1995-07-072015-07-07Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point226-230American Cyanamid Co.; British Patent 933,867; August 14, 1963.
water solubilityPractically insolubleNot Available
logP1.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0374 mg/mLALOGPS
logP2.2ALOGPS
logP1.56ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)13.73ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area93.06 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity111.89 m3·mol-1ChemAxon
Polarizability44.88 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassHydroxysteroids
Direct Parent21-hydroxysteroids
Alternative Parents
Substituents
  • 21-hydroxysteroid
  • Progestogin-skeleton
  • Pregnane-skeleton
  • 20-oxosteroid
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • Halo-steroid
  • 6-halo-steroid
  • 3-oxosteroid
  • 3-oxo-delta-1,4-steroid
  • Delta-1,4-steroid
  • Cyclic alcohol
  • Alpha-hydroxy ketone
  • Meta-dioxolane
  • Cyclic ketone
  • Secondary alcohol
  • Ketone
  • Oxacycle
  • Organoheterocyclic compound
  • Acetal
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Alkyl halide
  • Alkyl fluoride
  • Alcohol
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Hochhaus G, Moellmann HW: Binding affinities of rimexolone (ORG 6216), flunisolide and their putative metabolites for the glucocorticoid receptor of human synovial tissue. Agents Actions. 1990 Jun;30(3-4):377-80. [PubMed:2386110 ]
  2. Johnson M: Development of fluticasone propionate and comparison with other inhaled corticosteroids. J Allergy Clin Immunol. 1998 Apr;101(4 Pt 2):S434-9. [PubMed:9563368 ]
  3. Valotis A, Hogger P: Significant receptor affinities of metabolites and a degradation product of mometasone furoate. Respir Res. 2004 Jul 22;5:7. [PubMed:15285788 ]
  4. Hogger P, Erpenstein U, Rohdewald P, Sorg C: Biochemical characterization of a glucocorticoid-induced membrane protein (RM3/1) in human monocytes and its application as model system for ranking glucocorticoid potency. Pharm Res. 1998 Feb;15(2):296-302. [PubMed:9523318 ]
  5. Badia L, Lund V: Topical corticosteroids in nasal polyposis. Drugs. 2001;61(5):573-8. [PubMed:11368283 ]
  6. Philibert D, Bouchoux F, Cerede E, Corallo F, Allaire JM: [Pharmacologic study of the glucocorticoid activity of flunisolide compared with other steroids in the rat]. Allerg Immunol (Paris). 1993 Feb;25(2):77-81. [PubMed:8466638 ]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da

Carriers

Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Steroid binding
Specific Function:
Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
Gene Name:
SERPINA6
Uniprot ID:
P08185
Molecular Weight:
45140.49 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 02, 2016 02:42